India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.